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Abstract
Background: The aim of this study is to review all features of incidentally discovered prostate adenocarcinoma in
patients undergoing radical cystoprostatectomy for bladder cancer.
Methods: The medical charts of 300 male patients who underwent radical cystoprostatectomy for bladder cancer
between 1997 and 2005 were retrospectively reviewed. The mean age of the patients was 62 (range 51-75) years.
Results: Prostate adenocarcinoma was present in 60 (20%) of 300 specimens. All were acinar adenocarcinoma. Of
these, 40 (66.7%) were located in peripheral zone, 20 (33.3%) had pT2a tumor, 12 (20%) had pT2b tumor, 22(36.7%)
had pT2c and, 6 (10%) had pT3a tumor. Gleason score was 6 or less in 48 (80%) patients. Surgical margins were
negative in 54 (90%) patients, and tumor volume was less than 0.5 cc in 23 (38.3%) patients. Of the 60 incidentally
detected cases of prostate adenocarcinoma 40 (66.7%) were considered clinically significant.
Conclusion: Incidentally detected prostate adenocarcinoma is frequently observed in radical cystoprostatectomy
specimens. The majority are clinically significant.
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Background
Prostate adenocarcinoma (PCa) is the most common
visceral malignancy in the male population and the sec-
ond leading cause of death in men [1]. It can be found
incidentally when the prostate is removed during radical
cystoprostatectomy (RCP) for bladder cancer and
latently at autopsy or clinically diagnosed by physical
examination, laboratory tests, and symptoms [2,3]. In
autopsy series incidental prostate cancer is found in 30%
of men in their fifth decade and that rate increases to as
high as 90% in men aged older than 90 years [4]. The
frequency of PCa incidentally discovered in RCP speci-
mens is extremely variable, ranging from 10% to nearly
60% [1,3,5]. These tumors are typically small, well- or
moderately well-differentiated, localized entirely within
the gland, and most being regarded as clinically insignif-
icant [3,6].
Our aim was to review features of incidentally discov-
ered prostate adenocarcinoma in patients with bladder
cancer with regard to their incidence, pathologic charac-
teristics and clinical significance.
Methods
We reviewed the medical charts of 300 men who diag-
nosed muscle-invasive bladder urothelial carcinoma and
no history or clinical evidence of PCa before surgery in
1997-2005. Of these, 60 patients who had concomitant
PCa were included in our study. Physical examinations,
laboratory studies, chest radiographies and abdomino-
pelvic computed tomography were performed in all
patients. The clinical records were obtained at the time
of admission, and follow-up information was obtained
from hospital records or directly from the patient’s
families. Patients were evaluated considering to age,
tumor focality, tumor location, gleason score, pathologi-
cal tumor stage, extracapsular extension, seminal vesicle
invasion, surgical margin status, tumor volume and clin-
ical significance. The serum prostate-specific
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RCP
Histopathological findings were obtained surgically
resected specimens from the Department of Pathology
files that were evaluated by two pathologists. A routine
pathological examination was used for all RCP speci-
mens by sectioning and totally submitting the prostate.
The prostate was severed from the bladder and then
covered with India ink. After fixation for 24 h in 10%
neutral buffered formalin, the prostate specimens were
step sectioned at 3 mm intervals perpendicular to the
long axis (apical-basal) of the gland. (Between 1997 and
2002, some of the prostate specimens were sliced at an
interval of 5 mm). The apex, base and seminal vesicles
were removed from each specimen and submitted in
total for routine histological examination. The cut speci-
mens examined histological as 2 μm-thick whole-mount
haematoxylin and eosin (H&E)-stained sections. The
stage of prostate cancer was based on the 2002 revision
of the TNM system [7]. The Gleason score was deter-
mined using the 2005 International Society of Urological
Pathology modified Gleason system [8]. Tumor volume
was calculated using the length (L), width (W), and
height (number of cross sections × sectional thickness,
CST). According to Chen et al. derived the formula =
0.4 (slope of the regression line) × L × W × CST to esti-
mate volume [9].
We defined clinically significant PCa features as any of
the following: PCa tumor volume ≥ 0.5 cc, Gleason
score ≥ 6, extraprostatic extension, seminal vesicle inva-
sion, and/or a positive surgical margin according to the
criterion advocated by Epstein et al. [10]. Data for the
present study were identified by a structured MEDLINE
search up to 1st September 2010. ‘’Bladder cancer’’,
‘’cystoprostatectomy’’, ‘’incidental’’, and ‘’prostate cancer’’
were the key words for searching the data. Only publica-
tions in English were considered. All the studies addres-
sing the incidence, pathological characteristics, and/or
clinical significance of prostate tumors were included
and reviewed in detail
Results
In this study, a total of 60 patients (20%) were inciden-
tally diagnosed as having PCa in RCP specimens.
Detailed characteristics of these 60 are summarized in
Table 1. The mean age of the patients was 62 (range
51-75) years. All were acinar adenocarcinoma. Of the 20
adenocarcinoma (33.3%) were pT2a, whereas 12 (20%)
and 22(36.6%) were pT2b and pT2c, respectively and 6
adenocarcinoma (10%) was T3a. Of these patients, 32
(53.3%) had clinically signifi c a n tf e a t u r e s .1 2( 2 0 % )h a d
Gleason score of > 6, 37(61.7%) had PCa tumor volume
≥ 0.5 cc, 6(10%) had positive surgical margin and 6
(10%) had positive extraprostatic extension. Preoperative
PSA was high in 5 patients (ranging between 10-29.05
ng/ml). The characteristics of their PCa were stage T2
in 2 of them and stage T3 in others. Tumor volume was
significantly high in these patients. The surgical margin
was positive in one of these patients. In 48 specimens
(80%), the Gleason score was 6 or less. Negative margins
were present in 54 (90%) of cases. Negative
Table 1 The clinicopathological characteristics of
incidental prostate cancer at RCP in the 60 patients with
bladder cancer
Features Number of patient’s n (%)
Mean age at surgery, years 62
Focality
Monofocal 46
Multifocal 14
Tumor location
Peripheral zone 40
Central zone 6
Transition zone 2
All three zones 12
Gleason score
≤ 64 8
7 (3+4) 6
7 (4+3) 6
8-10 -
pT (TNM system)
pT2a 20
pT2b 12
pT2c 22
pT3a 6
pT3b -
pT4 -
Stage of bladder cancer 8
pT 1 2 0
p T2a 26
p T2b 6
p T3a
Seminal vesicle invasion
Negative 60
Positive -
Extraprostatic extension
Negative 54
Positive 6
Surgical margin status
Negative 54
Positive 6
Tumor volume, mL
Range 23
< 0.5 37
≥ 0.5
Clinically insignificant 20
Clinically significant 40
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cases. None of the patients had seminal vesicle invasion.
All cases were pN0 for PCa. In 23 specimens (38.3%),
the volume was less than 0.5 cc. Of the 60 cases of inci-
dentally detected prostate cancer, 40 (66.7%) were con-
sidered clinically significant. Follow-up data were
available for 60 patients. The cause of death was not
related to the PCa in any of the patients and there was
no PSA recurrence during follow-up of 96 months
(range between 72-168 months).
Discussion
RCP represents the most effective treatment for muscle-
invasive nonmetastatic bladder cancer [11]. Many
authors have reported a higher prevalence of PCa in
patients with bladder cancer [12,13], although data are
sparse regarding the outcome of these patients [14].
The frequent high coincidence of prostate and bladder
cancer occurring together could be explained by a com-
mon carcinogenic pathway. In this respect, Singh et al.
reported that some tumor suppressor genes such as p53
and Rb play a major role in the development of both
prostate and bladder cancers [15]. More recently, Amara
et al. demonstrated that prostate stem cell antigen is
overexpressed in most human transitional cell carcino-
mas in an immune-histochemical analysis [16]. How-
ever, these represent preliminary experiences and the
model for a common carcinogenic pathway remains to
be elucidated [1].
According to literature, the proportion of clinically
significant cancers in the series published previously var-
ies from 10% to 70% [4-6,12,14,17-33] [Table 2]. This
high range between the proportions may be related with
hereditary and exogenous factors, such as food con-
sumption and patterns of sexual behavior. The detailed
pathological examination of the excised prostatic tissue
specimens may be another important factor for the
detection of small cancer [31]. In this respect, two
important issues are the thickness of the slice of the
prostate and whether the prostate is totally embedded
[3]. The advantage of complete sampling over partial
sampling is that small foci of cancer are seen more fre-
quently. When prostate slices are thicker than 5 mm,
small foci of cancer might miss within the slice. By com-
plete sampling, cancer features, such as extraprostatic
extrusion and positive margins, are more accurately
evaluated [16]. Regarding the published reports in Table
2, Mazzucchelli et al [3] found a 49.6% rate of incidental
Table 2 PCa in cystoprostatectomy specimens: literature overview.
References Year No.of
Patients
Mean age
(year)
Slice Thickness
(mm)
Sampling of
prostate
No. of prostate
cancer (%)
No. of significant prostate
cancer (%)
Abbas [17] 1996 40 64.3 2-3 Partial 18(45) 6(33)
Moutzouris
[18]
1999 59 66.5 5 Complete 16 (27) NA
Aydin [19] 1999 121 67.1 NA NA 17 (14.0) NA
Yang [20] 1999 49 67 8 3 Complete 16 (33) NA
Conrad [21] 2001 133 60 3 Complete 58 (43.6) 11 (19)
Prange [22] 2001 85 64 4 Complete 41(48) 4(10)
Cindolo [23] 2001 165 69 3 Partial/complete 17(10.3) NA
Ward [24] 2004 129 69 NA NA 30(23.3) 18(60)
Revelo [25] 2004 121 67.4 5 Complete 50(41.3) 24(48)
Kouriefs [26] 2005 128 NA NA NA 23(18.0) NA
Delongchamps
[14]
2005 141 62 4 Complete 20(14.2) 14(70)
Ruffion [12] 2005 100 62 2.5 Complete 51 (51.0) 6 (12)
Lee [6] 2006 248 63.5 NA Complete 10 (4.0) NA
Rocco [27] 2006 63 67 3 Complete 34 (54) 12 (35)
Abdelhady [5] 2007 204 67 NA Complete 58 (28.4) 18 (31)
Winkler [32] 2007 97 NA 2 Partial 58 (60) 31 (53)
Hosseini [28] 2007 50 62.5 NA Partial 7 (14) 4 (57)
Weizer [29] 2007 35 65 NA NA 16 (46) 4 (25)
Jin [31] 2008 264 70.9 5 Complete 37 (14) 12 (32.4)
Mazzucchelli
[4]
2009 248 68 3 Complete 123 (49.6) 23 (18.7)
Nakagawa [33] 2009 349 65 5 NA 91 (26.1) 68 (74.7)
Gakis [30] 2010 95 68 4-5 NA 26 (27) 7 (27)
Present study 2010 300 62 3-5 Complete 60(20) 40(66.6)
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3-mm intervals. However, the incidence was lower in
studies using a different pathological examination proto-
col. For instance, Jin et al. identified PCa in 14% of the
examined specimens when using 5-mm thick slices [31].
In our study between 1997 and 2002 the prostate spe-
cimens were sliced at an interval of 5 mm. At the same
interval 160 patients were underwent RCP and only 14
patients (8.75%) with incidental PCa were identified.
Probably several incidental cancers might have been
missed in this interval. After 2002 prostate specimens
were evaluated with slices taken every 3 mm from the
base to the apex of the gland, as is usually done for
RCP, there was incidental PCa in 46 of 140 patients
(32.8%) who underwent RCP. We believe that using
slices taken every 2-3 mm, could detect a higher inci-
dence of PCa.
Stamey et al. first defined the clinically significant ade-
nocarcinoma of PCa in RCP specimens [34]. According
to these autours clinically significant prostate cancer is
based on Gleason score, tumour volume and stage,
lymph node status and resection margin [34]. After than
Epstein et al. defined clinically insignificant PCa fea-
tures: (1) a Gleason score ≤ 6 without Gleason pattern 4
or 5, (2) organ-confined disease (no extraprostatic
extension, seminal vesicle invasion, or lymph node
involvement and (3) a tumour volume < 0.5 cm3 [10].
We evaluated clinically significant PCa features as any
of the following: PCa tumor volume > 0.5 cc, Gleason
score > 6, extracapsular extension, seminal vesicle inva-
sion, and/or a positive surgical margin according to the
criterion advocated by Epstein et al. According to this
definition, the ratio of clinically significant PCa in our
study was 66.7% (40/60) and this is a remarkable ratio.
Careful preoperative evaluation to diagnose concurrent
PCa is very important [30]. Some authors have tried to
use PSA into predictive models of tumor significance.
Stamey et al. reported that serum PSA had been asso-
ciated with cancer volume [34]. Winkler investigated the
relationship between PSA level and tumour volume for
incidental adenocarcinoma of the prostate found in RCP
specimens. According to this study, the median PSA
level for patients with and without prostate cancer was
not significantly different [32]. The correlation between
tumor volume and PSA level is also controversial [32].
Although in our series, tumor volume was high in
patients with elevated levels of PSA, the number of
these patients is not enough to advocate this relation-
ship. In patients with PSA > 4 ng/mL or a palpable
nodule a meticulous dissection of prostate during RCP
should be performed.
According to Delongchamps et al. the outcome of
patients with incidental prostate ca after RCP depends
on the prognosis of bladder tumor [14]. In their report
on 141 patients, twenty of them had incidental PCa and
no patient experienced PSA recurrence during the fol-
low-up. [14]. Pritchett et al. reported no worse survival
in patients with both cancers compared with those with
bladder cancer alone [35]. Wolters et al demonstrated
that screen detected prostate cancer treated with radical
prostatectomy shows more aggressive features than inci-
dentally found prostate cancer [36]. In our study, PSA
did not reach the nadir < 0.2 ng/mL (considered the
cut-off value of biochemical recurrence for PCa) in a
mean follow-up of 96 months (range, 72-168 months).
All of the patients with incidental PCa were still alive.
These findings show that incidental PCa does not influ-
ence prognosis and suggest that the outcome of patients
with incidentally discovered PCa after RCP depends on
the prognosis of the bladder cancer.
Conclusions
The reported incidence of PCa in RCP specimens is
highly variable and mostly depending on the histo-
pathology technique of sampling. PSA cannot identify
asymptomatic PCa, so there is still no effective tool for
the detection of PCa before surgery. In line with pub-
lished reports, incidental PCa does not impact the prog-
nosis of bladder cancer patients undergoing RCP. The
clinical significance of these incidentally discovered can-
cers remains questionable, as the outcome of patients
depends on the prognosis of the bladder tumor.
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